Intelligent Hotel Group Ltd.

ZHJD
About the company

Intelligent Hotel Group Ltd does not have significant operations. Previously, the company was engaged in the bio-carbon-based fertilizer (BCBF) trading, online retailing, and beauty products trading businesses. It evaluates acquisition targets and strategic business opportunities to enter industries, such as hotel, cinema, green energy, and automotive.

Country: United StatesPrice: $1.78Market Cap: $180.5M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

2 / 14

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

All 13 investors flag ZHJD's valuation

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2024 · Balance sheet at 2025-09-30

Latest source filing: 2025-10-23

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-07-17

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-07-17

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-07-17

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-07-17

Score computed: 2026-11-14

Annual history · FY 2024 · Balance sheet at 2025-09-30 · Market data at 2026-11-01

Latest source filing: 2025-10-23

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2025-07-17

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2024

Latest source filing: 2025-07-17

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-07-17

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-07-17

Score computed: 2026-11-14

Annual history · FY 2024 · Market data at 2026-11-01

Latest source filing: 2025-07-17

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-07-17

Score computed: 2026-11-14

Annual history · FY 2024 · Qualitative assessment

Latest source filing: 2025-07-17

Score computed: 2026-11-14

Annual history · FY 2024 · Balance sheet at 2025-09-30 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-10-23

Score computed: 2026-11-14

Annual history · FY 2024

Latest source filing: 2025-07-17

Score computed: 2026-11-14

Annual history · FY 2024 · Balance sheet at 2025-09-30

Latest source filing: 2025-10-23

Score computed: 2026-11-14

Annual history · FY 2024 · Price history 2025-01-01–2026-11-01

Latest source filing: 2025-07-17

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✗ 28▾

      All 13 investors flag ZHJD's valuation

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-0.0%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-0.0%, ROC=None
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per ShareN/A (negative BVPS)
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation Reasonableness
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical Average
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share
      ✗Ackman<= 25
      Price vs. Trailing Low539% of trailing low ($0.33)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-0.03%; #3204/6340 (top 50.5%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization-0.0001; #5262/6449 (top 81.6%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.0014; #5006/5247 (top 95.4%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date+13.38%; #1675/6202 (top 27.0%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✗ 12▾

      All 10 investors flag ZHJD's cash flow

      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      FCF Positive and Growing
      ✗LynchPositive and growing
      Operating Cash Flow$-0.1M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-85.17%, ROA=-43.50%
      ✗PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap
      ✗Ackman>= 4%
      Price / FCF per Share
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency1/5 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 3✗ 10▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: -78.7% vs Rev: -51.7%
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction$0.00 (2020) -> $0.00 (2024)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency1/5 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth12.4%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency0/4 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 83.6% -> 39.1%, operating margin -63.0% -> -19.1%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency0% pass✓ 1✗ 10▾

      No clean pass — all 8 investors flag at least one efficiency criterion

      Current Ratio0.08
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)
      ✗Buffett> 10%
      ROIC - WACC
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)
      ✗Greenblatt> 25%
      Current Ratio Change YoY0.57 -> 0.33
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY1.35x -> 1.81x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities0.08
      ✗Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2022: ROIC=unavailable; FY2023: ROIC=unavailable; FY2024: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)
      ✗SleepROIC > 12% in a majority of years
    • Verdicts0% pass✗ 14▾

      Split decision: 14 FAIL · 2 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (0/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (0/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✗AckmanFAIL (2/9)✗TempletonFAIL (2/8)✗SleepFAIL (2/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (1/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked)
    • Profitability6% pass✓ 4✗ 31▾

      15 of 16 flag ZHJD's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)0/6 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)1/6 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-19.1% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROEN/A (negative equity)
      ✗Lynch> 15%
      EBIT / Enterprise Value-0.0%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-0.0%, ROC=None
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-43.50%
      ✗PiotroskiROA > 0
      ROA Change YoY2.65% -> -43.50% (delta: -46.14%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-85.17%, ROA=-43.50%
      ✗PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY86.3% -> 39.1%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-20.9%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity
      ✗Dreman> 12%
      Margin of Safety
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency1/5 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-19.1%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-63.0% (2022) -> -19.1% (2024)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 83.6% -> 39.1%, operating margin -63.0% -> -19.1%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-0.03%; #3204/6340 (top 50.5%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+70.80%; #334/3702 (top 9.0%)
      ✓AsnessTop 30% of eligible cross-section
      Net income / positive book equity
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.5768; #5022/5884 (top 85.4%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years0/5 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Debt & Leverage8% pass✓ 1✗ 14▾

      11 of 12 flag ZHJD's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities0.08
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDA
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2024. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Chemicals
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Micro Cap($180.5M)
    Revenue: $246466.00-51.7% YoY
    Net Income: $-59275.00-693.4% YoY

    Financial Snapshot

    Operating Margin-19.1%
    Return on Equity21.0%
    Debt / Equity--
    Current Ratio0.33
    EPS (Diluted)$0.00
    Shares Retired0.0% / 0.0% 2y

    Shareholder Return

    Fiscal 2024

    Retired 0.0% of shares last year, 0.0% over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricQ3 FY 2025

    2025-07-01 – 2025-09-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow.

    Q2 FY 2025

    2025-04-01 – 2025-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow.

    Q1 FY 2025

    2025-01-01 – 2025-03-31

    Sources
    FY 2024
    Sources
    • 10-K · 2025-07-17
    FY 2023
    Sources
    • 10-K · 2024-04-16
    FY 2022
    Sources
    • 10-K · 2023-03-30
    FY 2021
    Sources
    • 10-K · 2022-03-31
    FY 2020
    Sources
    • 10-K · 2022-03-31
    Market Cap$180.5Mcurrent----$37.5Mest.$101.4Mest.$101.4Mest.$20.3Mest.--
    Revenue------$246.5K↓52%$510.2K↑331%$118.4K↑12%$105.3K↑54%$68.3K
    Operating Income-$22.7K↑10%-$76.1K↑2%-$6.9K↓104%-$47.1K↓788%$6.8K↑109%-$74.5K↑66%-$222.2K↓147%-$89.8K
    Net Income-$22.7K↑10%-$151.9K↓79%-$6.9K↓104%-$59.3K↓693%$10.0K↑113%-$74.5K↑66%-$222.1K↓148%-$89.7K
    EPS (Diluted)------$0.00$0.00$0.00$0.00$0.00
    Gross Margin———39.1%↓55%86.3%↑3%83.6%↑83%45.7%↓1%46.1%
    Operating Margin———-19.1%↓1524%1.3%↑102%-63.0%↑70%-211.0%↓60%-131.5%
    ROE———21.0%↑561%-4.6%↓114%33.4%↓79%160.0%↓38%258.6%
    Total Debt----------------
    Shareholders' Equity-$10.8K↑94%-$40.1K↑74%-$286.6K↓333%-$281.8K↓29%-$219.1K↑2%-$223.1K↓61%-$138.8K↓300%-$34.7K
    Current Ratio0.08↓88%0.02↓97%0.28↓67%0.33↓43%0.57↑6%0.54↑23%0.44↓46%0.82
    Debt / Equity————————
    Operating Cash Flow-$63.5K↓131%-$18.5K↑89%-$27.4K↓123%-$116.1K↑64%-$318.2K↓364%$120.5K↑174%-$161.8K↓372%-$34.3K
    Free Cash Flow----------------

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Chemicals

    ZHJD vs Peers — Financial Grading

    Revenue$246466.00Bottom 25%
    Net Income$-59275.00Bottom 25%
    ROE21.0%Median
    D/E—
    Op. Margin-19.1%Bottom 25%
    Curr. Ratio0.33Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    EIDP, Inc.CTA-PB$46.8B$54.21——————2/95/92/70/3F-Score 14/11
    CF Industries Holdings, Inc.CF$18.3B$125.09$7.1B$1.8B37.2%0.6632.5%3.373/94/95/73/3F-Score 88/11
    RPM INTERNATIONAL INC/DE/RPM$13.2B$103.73$7.9B$661.4M20.0%0.77—1.683/92/93/71/3F-Score 67/11
    Element Solutions IncESI$8.0B$33.08$2.6B$190.8M7.1%0.6113.4%3.682/92/91/71/3F-Score 56/11
    NEWMARKET CORPNEU$6.5B$709.19$2.7B$418.7M23.5%0.5020.0%2.534/96/92/71/3F-Score 55/11
    HEXCEL CORP /DE/HXL$6.0B$79.46$1.9B$109.4M8.7%0.799.1%2.262/92/93/70/3F-Score 64/11
    ICL Group Ltd.ICL$5.8B$4.52$7.2B$226.0M3.8%0.468.1%1.335/94/92/70/3F-Score 45/11
    BALCHEM CORPBCPC$5.5B$173.14$1.0B$154.8M12.3%0.1320.2%2.072/94/92/71/3F-Score 95/11